ENSC

Ensysce Biosciences, Inc.
CAPPED RATING

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Ensysce Biosciences, Inc. (ENSC) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.2
EV / EBITDA N/A
Rev Growth YoY -15.1%
Gross Margin N/M
Price Return 3M -9.8%
Price Return 12M -82.5%
Catalyst Signal 0.00
Market Cap $7.0M
TTM Revenue $4.5M
Price / Sales 1.6
ROE N/M

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) D (1.2) D+ (1.8) B (3.3) C+ (2.6) C (2.4)
2026-11-04 B- (3.0) D (1.2) C- (1.9) C+ (2.8) C+ (2.7) C (2.3)
2026-10-28 B- (3.0) D (1.2) C- (1.9) C+ (2.8) C+ (2.7) C (2.3)
2026-10-21 B- (3.0) D (1.5) C- (1.9) C+ (2.6) C+ (2.6) C (2.3)
2026-10-14 B- (3.0) D (1.5) C- (1.9) C+ (2.6) C+ (2.6) C (2.3)
Page 1 of 7